According to the popularly cited study from Tufts Center for the Study of Drug Development, it costs $2.6 billion to receive a drug approval.¹ Despite the increased investments and revolutionary therapies brought to market, return on investment from drug launches is near historical lows.² Luckily, issues such as challenging physicochemical properties and unfavorable absorption characteristics can be addressed early in the development process. Screening formulation options in the pre-clinical setting has the potential to reduce both costs and risk of attrition.

Full Article